Positive neurologic phenomena with initiation of dalfampridine for multiple sclerosis

Greg M. Thaera, Dean M. Wingerchuk, Jonathan L. Carter

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Objective Review cases of positive neurologic phenomena initiated or worsened with dalfampridine in patients with multiple sclerosis. Background Oral, extended release dalfampridine (4-aminopyridine or 4-AP) is a potassium-channel blocker approved for the treatment of gait impairment in multiple sclerosis (MS). The enhanced conduction along demyelinated axons promoted by dalfampridine could potentially lead to development of positive neurologic phenomena. Methods We reviewed the medical records of patients who were started on dalfampridine for activation of positive sensory or motor symptoms. Results Four of 76 patients (5.3%) developed positive sensory symptoms within one month of starting dalfampridine; one additional patient had new-onset seizure. Cessation of dalfampridine was insufficient to resolve symptoms in two patients with recurrent trigeminal neuralgia. Conclusions Initiation of dalfampridine may be associated with initiation or recurrence of positive sensory symptoms in patients with multiple sclerosis. The increased axonal conduction from potassium channel blockade may contribute to this exacerbation of positive sensory phenomena.

Original languageEnglish (US)
Pages (from-to)107-109
Number of pages3
JournalMultiple Sclerosis and Related Disorders
Issue number1
StatePublished - Jan 1 2014


  • Dalfampridine
  • Multiple sclerosis
  • Paroxysmal neurologic symptoms
  • Seizures
  • Sensation disorders
  • Trigeminal neuralgia

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Positive neurologic phenomena with initiation of dalfampridine for multiple sclerosis'. Together they form a unique fingerprint.

Cite this